Serious injuries prompt new US FDA labeling recommendations for dermal fillers
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has urged dermal filler firms to update labeling to warn of rare but serious complications that can occur when the soft tissue products are unintentionally injected into facial blood vessels in conjunction with a safety communication to providers and patients on the topic1.